About Amphastar Pharmaceuticals (NASDAQ:AMPH)
Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products. The finished pharmaceutical products segment manufactures, markets and distributes enoxaparin, Cortrosyn, Amphadase, naloxone, lidocaine jelly, as well as various other critical and non-critical care drugs. The API segment manufactures and distributes recombinant human insulin and porcine insulin. The Company also manufactures and sells insulin API. As of December 31, 2016, the Company manufactured and sold 19 products. As of December 31, 2016, the Company developed a portfolio of 15 generic abbreviated new drug applications (ANDAs) three generic biosimilar product candidates and six injectable and inhalation product candidates.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AMPH
CUSIPN/A
Phone909-980-9484
Debt
Debt-to-Equity Ratio0.12%
Current Ratio2.79%
Quick Ratio1.85%
Price-To-Earnings
Trailing P/E Ratio51.11
Forward P/E Ratio30.62
P/E Growth1.39
Sales & Book Value
Annual Sales$240.18 million
Price / Sales3.72
Cash Flow$0.7211 per share
Price / Cash26.75
Book Value$7.34 per share
Price / Book2.63
Profitability
EPS (Most Recent Fiscal Year)$0.38
Net Income$4.50 million
Net Margins1.88%
Return on Equity4.56%
Return on Assets3.41%
Miscellaneous
Employees1,644
Outstanding Shares46,350,000
Amphastar Pharmaceuticals (NASDAQ:AMPH) Frequently Asked Questions
What is Amphastar Pharmaceuticals' stock symbol?
Amphastar Pharmaceuticals trades on the NASDAQ under the ticker symbol "AMPH."
How will Amphastar Pharmaceuticals' stock buyback program work?
Amphastar Pharmaceuticals announced that its Board of Directors has approved a stock repurchase plan on Thursday, August 10th 2017, which allows the company to buyback $20,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization allows the company to repurchase up to 2.8% of its stock through open market purchases. Stock buyback plans are often an indication that the company's management believes its stock is undervalued.
How were Amphastar Pharmaceuticals' earnings last quarter?
Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) issued its quarterly earnings data on Monday, March, 12th. The company reported $0.10 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.07 by $0.03. The business earned $60.40 million during the quarter, compared to analyst estimates of $60.62 million. Amphastar Pharmaceuticals had a return on equity of 4.56% and a net margin of 1.88%. The business's revenue for the quarter was down 4.9% on a year-over-year basis. During the same period last year, the firm posted $0.01 EPS. View Amphastar Pharmaceuticals' Earnings History.
What price target have analysts set for AMPH?
6 brokerages have issued 1 year target prices for Amphastar Pharmaceuticals' stock. Their forecasts range from $18.00 to $26.00. On average, they expect Amphastar Pharmaceuticals' stock price to reach $21.20 in the next year. View Analyst Ratings for Amphastar Pharmaceuticals.
Who are some of Amphastar Pharmaceuticals' key competitors?
Some companies that are related to Amphastar Pharmaceuticals include Insmed (INSM), Cambrex (CBM), OPKO Health (OPK), MyoKardia (MYOK), Phibro Animal Health (PAHC), Madrigal Pharmaceuticals (MDGL), Enanta Pharmaceuticals (ENTA), Prestige Brands (PBH), Xencor (XNCR), Innoviva (INVA), Akcea Therapeutics (AKCA), Radius Health (RDUS), Impax Laboratories (IPXL), Pacira Pharmaceuticals (PCRX), Immuron (IMRN), Zogenix (ZGNX), Prothena (PRTA) and Myovant Sciences (MYOV).
Who are Amphastar Pharmaceuticals' key executives?
Amphastar Pharmaceuticals' management team includes the folowing people:
- Mary Ziping Luo Ph.D., Chief Operating Officer, Chief Scientist and Chairman of the Board (Age 67)
- Jason B. Shandell J.D., President, General Counsel, Director (Age 43)
- Jack Yongfeng Zhang Ph.D., Chief Executive Officer, Chief Scientific Officer, Director (Age 70)
- William J. Peters, Chief Financial Officer, Senior Vice President, Treasurer and President of Armstrong Pharmaceuticals, Inc. (Age 49)
- Diane G. Gerst, Executive Vice President - Quality Assurance and Regulatory Affairs and President of Amphastar Nanjing Pharmaceuticals Inc (Age 57)
- Rong Zhou, Executive Vice President - Production Center and President of Armstrong Pharmaceuticals, Inc. (Age 58)
- Michael A. Zasloff M.D. Ph.D., Lead Independent Director (Age 71)
- Richard Koo CPA, Independent Director (Age 76)
- Howard S. Lee Ph.D., Independent Director (Age 54)
- Floyd F. Petersen, Independent Director (Age 73)
Has Amphastar Pharmaceuticals been receiving favorable news coverage?
Media stories about AMPH stock have trended somewhat positive recently, Accern reports. Accern identifies negative and positive media coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Amphastar Pharmaceuticals earned a news impact score of 0.05 on Accern's scale. They also gave media stories about the company an impact score of 47.60 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.
How do I buy shares of Amphastar Pharmaceuticals?
Shares of AMPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Amphastar Pharmaceuticals' stock price today?
One share of AMPH stock can currently be purchased for approximately $19.29.
How big of a company is Amphastar Pharmaceuticals?
Amphastar Pharmaceuticals has a market capitalization of $906.62 million and generates $240.18 million in revenue each year. The company earns $4.50 million in net income (profit) each year or $0.38 on an earnings per share basis. Amphastar Pharmaceuticals employs 1,644 workers across the globe.
How can I contact Amphastar Pharmaceuticals?
Amphastar Pharmaceuticals' mailing address is 11570 SIXTH STREET, RANCHO CUCAMONGA CA, 91730. The company can be reached via phone at 909-980-9484 or via email at [email protected]
MarketBeat Community Rating for Amphastar Pharmaceuticals (AMPH)
MarketBeat's community ratings are surveys of what our community members think about Amphastar Pharmaceuticals and other stocks. Vote "Outperform" if you believe AMPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
Amphastar Pharmaceuticals (NASDAQ:AMPH) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
6 Wall Street analysts have issued ratings and price targets for Amphastar Pharmaceuticals in the last 12 months. Their average twelve-month price target is $21.20, suggesting that the stock has a possible upside of 9.90%. The high price target for AMPH is $26.00 and the low price target for AMPH is $18.00. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.67 | 2.67 | 2.67 | 2.83 |
| Ratings Breakdown: | 0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $21.20 | $21.20 | $19.20 | $20.1667 |
| Price Target Upside: | 9.90% upside | 8.66% upside | 1.99% downside | 9.01% upside |
Amphastar Pharmaceuticals (NASDAQ:AMPH) Consensus Price Target History
Amphastar Pharmaceuticals (NASDAQ:AMPH) Analyst Ratings History
Show:
(Data available from 4/20/2016 forward)
Amphastar Pharmaceuticals (NASDAQ:AMPH) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Amphastar Pharmaceuticals (NASDAQ AMPH) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 11.10%
Institutional Ownership Percentage: 44.50%
Amphastar Pharmaceuticals (NASDAQ AMPH) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 3/20/2018 | Jason B Shandell | Insider | Sell | 20,000 | $19.43 | $388,600.00 | 251,372 |  |
| 3/15/2018 | Richard K Prins | Director | Sell | 16,598 | $19.90 | $330,300.20 | 45,442 | |
| 3/14/2018 | Jason B Shandell | Insider | Sell | 700 | $20.45 | $14,315.00 | | |
| 3/13/2018 | William J Peters | CFO | Sell | 19,801 | $20.10 | $398,000.10 | | |
| 1/26/2018 | Jason B. Shandell | Insider | Sell | 18,627 | $19.42 | $361,736.34 | | |
| 1/25/2018 | Jason B. Shandell | General Counsel | Sell | 8,661 | $19.26 | $166,810.86 | | |
| 12/19/2017 | Diane G Gerst | EVP | Sell | 523 | $19.48 | $10,188.04 | 30,164 | |
| 12/14/2017 | Stephen B Shohet | Director | Sell | 7,866 | $18.87 | $148,431.42 | 31,982 | |
| 12/12/2017 | Diane G Gerst | EVP | Sell | 523 | $18.96 | $9,916.08 | 30,687 | |
| 12/7/2017 | Stephen B Shohet | Director | Sell | 7,862 | $18.34 | $144,189.08 | 31,978 | |
| 12/1/2017 | William J. Peters | CFO | Sell | 6,226 | $19.67 | $122,465.42 | | |
| 11/30/2017 | Stephen B Shohet | Director | Sell | 7,862 | $19.25 | $151,343.50 | 31,978 | |
| 11/28/2017 | Diane G Gerst | EVP | Sell | 523 | $18.15 | $9,492.45 | 31,210 | |
| 11/22/2017 | Stephen B Shohet | Director | Sell | 7,862 | $18.94 | $148,906.28 | 31,978 | |
| 11/21/2017 | Diane G Gerst | EVP | Sell | 523 | $18.81 | $9,837.63 | 31,733 | |
| 11/16/2017 | Stephen B Shohet | Director | Sell | 7,862 | $18.04 | $141,830.48 | 31,978 | |
| 11/15/2017 | Diane G Gerst | EVP | Sell | 523 | $17.77 | $9,293.71 | 32,256 | |
| 11/9/2017 | Stephen B Shohet | Director | Sell | 7,862 | $18.55 | $145,840.10 | 31,978 | |
| 11/7/2017 | Diane G Gerst | EVP | Sell | 523 | $17.93 | $9,377.39 | 32,779 | |
| 11/2/2017 | Stephen B Shohet | Director | Sell | 7,862 | $18.37 | $144,424.94 | | |
| 10/26/2017 | Stephen B Shohet | Director | Sell | 7,862 | $18.39 | $144,582.18 | 31,978 | |
| 10/24/2017 | Diane G Gerst | EVP | Sell | 523 | $18.29 | $9,565.67 | 33,302 | |
| 10/19/2017 | Stephen B Shohet | Director | Sell | 7,862 | $18.34 | $144,189.08 | 31,978 | |
| 10/17/2017 | Diane G Gerst | EVP | Sell | 523 | $18.48 | $9,665.04 | 33,825 | |
| 10/13/2017 | William J Peters | CFO | Sell | 3,026 | $18.56 | $56,162.56 | | |
| 10/12/2017 | Stephen B Shohet | Director | Sell | 7,862 | $18.73 | $147,255.26 | | |
| 10/5/2017 | Diane G Gerst | EVP | Sell | 8,444 | $18.87 | $159,338.28 | | |
| 10/4/2017 | Floyd F Petersen | Director | Sell | 39,312 | $18.59 | $730,810.08 | | |
| 10/2/2017 | Michael A Zasloff | Director | Sell | 63,624 | $18.18 | $1,156,684.32 | 101,879 | |
| 8/15/2017 | Richard K Prins | Director | Sell | 10,000 | $14.81 | $148,100.00 | 33,844 | |
| 8/14/2017 | Richard K Prins | Director | Sell | 5,000 | $14.80 | $74,000.00 | 33,844 | |
| 6/9/2017 | Richard K Prins | Director | Sell | 10,000 | $17.07 | $170,700.00 | 28,844 | |
| 6/1/2017 | Michael A Zasloff | Director | Sell | 15,000 | $17.01 | $255,150.00 | 47,411 | |
| 5/31/2017 | Jason B Shandell | Director | Sell | 11,482 | $16.92 | $194,275.44 | 241,342 | |
| 5/11/2017 | Richard K Prins | Director | Sell | 7,500 | $15.43 | $115,725.00 | 30,500 | |
| 1/3/2017 | Floyd F Petersen | Director | Sell | 400 | $18.61 | $7,444.00 | 58,717 | |
| 12/15/2016 | Diane G Gerst | EVP | Sell | 2,940 | $20.51 | $60,299.40 | 26,195 | |
| 12/5/2016 | Rong Zhou | EVP | Sell | 61 | $20.70 | $1,262.70 | 36,991 | |
| 12/1/2016 | Floyd F Petersen | Director | Sell | 400 | $20.26 | $8,104.00 | 59,117 | |
| 11/28/2016 | Jason B Shandell | Insider | Sell | 26,335 | $20.48 | $539,340.80 | 205,004 | |
| 11/15/2016 | Howard Lee | Director | Sell | 37,994 | $20.65 | $784,576.10 | 134,527 | |
| 10/3/2016 | Floyd F Petersen | Director | Sell | 400 | $18.75 | $7,500.00 | 59,917 | |
| 9/26/2016 | Jason B Shandell | Insider | Sell | 56,996 | $19.50 | $1,111,422.00 | 259,957 | |
| 9/20/2016 | Jack Y Zhang | CEO | Sell | 444,199 | $21.03 | $9,341,504.97 | 1,295,685 | |
| 9/8/2016 | Floyd F Petersen | Director | Sell | 3,000 | $19.05 | $57,150.00 | 60,317 | |
| 9/1/2016 | Howard Lee | Director | Sell | 10,381 | $18.78 | $194,955.18 | 125 | |
| 8/22/2016 | Jason B Shandell | General Counsel | Sell | 10,000 | $19.95 | $199,500.00 | 212,961 | |
| 8/19/2016 | Diane G Gerst | EVP | Sell | 24,046 | $19.28 | $463,606.88 | 39,031 | |
| 8/18/2016 | Richard K Prins | Director | Sell | 3,086 | $19.62 | $60,547.32 | 26,000 | |
| 8/17/2016 | Jason B Shandell | Insider | Sell | 5,987 | $18.86 | $112,914.82 | 202,961 | |
| 8/16/2016 | Stephen B Shohet | Director | Sell | 48,375 | $18.24 | $882,360.00 | 28,653 | |
| 8/15/2016 | Michael A Zasloff | Director | Sell | 48,375 | $18.15 | $878,006.25 | 42,792 | |
| 8/12/2016 | William J Peters | CFO | Sell | 1,027 | $18.19 | $18,681.13 | 63,625 | |
| 8/11/2016 | Jason B Shandell | President | Sell | 5,636 | $18.01 | $101,504.36 | 208,948 | |
| 8/11/2016 | Richard K Prins | Director | Sell | 13,993 | $18.03 | $252,293.79 | 31,681 | |
| 7/18/2016 | William J Peters | CFO | Sell | 2,297 | $17.76 | $40,794.72 | 64,652 | |
| 6/15/2016 | Rong Zhou | EVP | Sell | 1,551 | $15.85 | $24,583.35 | 37,137 | |
| 6/13/2016 | Richard K Prins | Director | Sell | 7,500 | $15.94 | $119,550.00 | 29,086 | |
| 6/9/2016 | Jason B Shandell | President | Sell | 9,904 | $16.43 | $162,722.72 | 216,610 | |
| 6/2/2016 | William J Peters | CFO | Sell | 2,297 | $16.00 | $36,752.00 | 66,949 | |
| 5/25/2016 | Jason B Shandell | President | Sell | 1,074 | $15.60 | $16,754.40 | 226,514 | |
| 5/18/2016 | Diane G Gerst | EVP | Sell | 1,427 | $13.97 | $19,935.19 | 28,649 | |
| 5/17/2016 | Richard K Prins | Director | Sell | 3,200 | $13.56 | $43,392.00 | 23,000 | |
| 4/19/2016 | Diane G Gerst | EVP | Sell | 21,244 | $12.89 | $273,835.16 | 39,713 | |
| 4/18/2016 | Diane G Gerst | EVP | Sell | 15,637 | $12.83 | $200,622.71 | 39,713 | |
| 3/17/2016 | Richard K Prins | Director | Sell | 2,400 | $11.25 | $27,000.00 | 26,200 | |
| 12/17/2015 | Stephen B. Shohet | Director | Sell | 30,770 | $14.19 | $436,626.30 | 12,186 | |
| 12/16/2015 | Howard Lee | Director | Sell | 38,462 | $14.34 | $551,545.08 | 109,901 | |
| 12/16/2015 | Rong Zhou | EVP | Sell | 772 | $14.29 | $11,031.88 | 25,460 | |
| 12/11/2015 | Jack Y Zhang | CEO | Sell | 63,300 | $14.25 | $902,025.00 | 920,117 | |
| 12/8/2015 | Jack Y Zhang | CEO | Sell | 68,117 | $14.71 | $1,002,001.07 | 920,117 | |
| 12/3/2015 | Jack Y Zhang | CEO | Sell | 38,583 | $15.45 | $596,107.35 | 920,117 | |
| 8/18/2015 | Richard K Prins | Director | Sell | 9,100 | $14.66 | $133,406.00 | | |
| 8/17/2015 | Richard K. Prins | Director | Sell | 5,400 | $14.70 | $79,380.00 | 35,722 | |
| 7/17/2015 | Michael A Zasloff | Director | Sell | 7,692 | $17.41 | $133,917.72 | | |
| 6/17/2015 | Rong Zhou | EVP | Sell | 1,000 | $16.48 | $16,480.00 | | |
| 6/15/2015 | Jack Y Zhang | CEO | Sell | 45,382 | $16.29 | $739,272.78 | | |
| 6/12/2015 | Jack Y Zhang | CEO | Sell | 160,495 | $16.23 | $2,604,833.85 | | |
| 6/9/2015 | Jack Y Zhang | CEO | Sell | 193,758 | $16.43 | $3,183,443.94 | | |
| 5/22/2015 | Richard K Prins | Director | Sell | 29,452 | $14.77 | $435,006.04 | | |
| 5/19/2015 | Richard K Prins | Director | Sell | 3,000 | $14.94 | $44,820.00 | | |
| 4/9/2015 | Marilyn J Purchase | VP | Sell | 28,000 | $15.79 | $442,120.00 | | |
| 4/8/2015 | Diane G Gerst | SVP | Sell | 10,000 | $15.79 | $157,900.00 | | |
| 8/25/2014 | Howard Lee | Director | Buy | 6,000 | $10.84 | $65,040.00 | | |
| 8/19/2014 | Michael A Zasloff | Director | Buy | 3,500 | $10.00 | $35,000.00 | | |
| 8/18/2014 | Richard K Prins | Director | Buy | 4,000 | $10.02 | $40,080.00 | | |
| 8/15/2014 | Floyd F Petersen | Director | Buy | 3,200 | $10.35 | $33,120.00 | | |
(Data available from 1/1/2013 forward)
Amphastar Pharmaceuticals (NASDAQ AMPH) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Amphastar Pharmaceuticals Inc (AMPH) Expected to Post Quarterly Sales of $63.15 Million
www.americanbankingnews.com - April 17 at 4:00 AM |
| Amphastar Pharmaceuticals Inc (AMPH) Expected to Announce Earnings of $0.09 Per Share
www.americanbankingnews.com - April 15 at 11:15 AM |
| Amphastar Pharmaceuticals Inc (AMPH) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - April 4 at 5:52 PM |
 | What Is Amphastar Pharmaceuticals Inc’s (NASDAQ:AMPH) Share Price Doing?
finance.yahoo.com - April 4 at 5:17 PM |
| Amphastar Pharmaceuticals (AMPH) Downgraded by Raymond James Financial to "Market Perform"
www.americanbankingnews.com - March 31 at 6:34 PM |
| Amphastar Pharmaceuticals Inc (AMPH) Expected to Announce Quarterly Sales of $63.15 Million
www.americanbankingnews.com - March 31 at 3:00 AM |
| Amphastar Pharmaceuticals (AMPH) Downgraded by BidaskClub
www.americanbankingnews.com - March 30 at 9:17 AM |
 | Amphastar Pharmaceuticals (AMPH) Presents At Needham and Company 17th Annual Healthcare Conference - Slideshow
seekingalpha.com - March 29 at 4:16 PM |
| Analysts Expect Amphastar Pharmaceuticals Inc (AMPH) to Post $0.09 EPS
www.americanbankingnews.com - March 29 at 1:52 PM |
| Is Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) A Sell At Its Current PE Ratio?
finance.yahoo.com - March 28 at 9:57 AM |
 | Amphastar Pharmaceuticals to Present at the Needham's 17th Annual Healthcare Conference
globenewswire.com - March 26 at 4:09 PM |
| Amphastar Pharmaceuticals (AMPH) Earns Buy Rating from Piper Jaffray
www.americanbankingnews.com - March 26 at 1:26 PM |
| Amphastar Pharmaceuticals to Present at the Needham’s 17th Annual Healthcare Conference
finance.yahoo.com - March 26 at 10:11 AM |
 | Amphastar Pharma (AMPH) Reports Favorable Final Judgement in Patent Litigation Against Momenta Pharmaceuticals Inc. and Sandoz Inc.
www.streetinsider.com - March 23 at 9:39 AM |
| Amphastar Pharmaceuticals' (AMPH) Buy Rating Reaffirmed at Wells Fargo
www.americanbankingnews.com - March 22 at 10:54 PM |
| Amphastar Announces Final Judgment in the Patent Litigation against Momenta Pharmaceuticals, Inc. and Sandoz Inc. - GlobeNewswire (press release)
globenewswire.com - March 22 at 4:11 PM |
| Head to Head Comparison: Pernix Therapeutics (PTX) vs. Amphastar Pharmaceuticals (AMPH)
www.americanbankingnews.com - March 21 at 1:20 PM |
| Amphastar Pharma (AMPH) Reports Favorable Final Judgement in Patent Litigation Against Momenta Pharmaceuticals ... - StreetInsider.com
www.streetinsider.com - March 21 at 10:55 AM |
 | Amphastar Announces Final Judgment in the Patent Litigation against Momenta Pharmaceuticals, Inc. and Sandoz Inc. - Nasdaq
www.nasdaq.com - March 21 at 10:55 AM |
| Amphastar Announces Final Judgment in the Patent Litigation against Momenta Pharmaceuticals, Inc. and Sandoz Inc.
finance.yahoo.com - March 21 at 10:54 AM |
| Jason B. Shandell Sells 20,000 Shares of Amphastar Pharmaceuticals Inc (AMPH) Stock
www.americanbankingnews.com - March 20 at 10:14 PM |
| Amphastar Pharmaceuticals (AMPH) Raised to Hold at BidaskClub
www.americanbankingnews.com - March 18 at 7:10 PM |
| Richard K. Prins Sells 16,598 Shares of Amphastar Pharmaceuticals Inc (AMPH) Stock
www.americanbankingnews.com - March 16 at 7:52 PM |
| Aquinox Pharmaceuticals (AQXP) and Amphastar Pharmaceuticals (AMPH) Head-To-Head Comparison
www.americanbankingnews.com - March 16 at 1:06 PM |
| Jefferies Group Weighs in on Amphastar Pharmaceuticals Inc's FY2018 Earnings (AMPH)
www.americanbankingnews.com - March 16 at 10:48 AM |
| Amphastar Pharmaceuticals Inc (AMPH) Insider Jason B. Shandell Sells 700 Shares
www.americanbankingnews.com - March 15 at 8:30 PM |
| William J. Peters Sells 19,801 Shares of Amphastar Pharmaceuticals Inc (AMPH) Stock
www.americanbankingnews.com - March 15 at 7:46 PM |
| Research Analysts Offer Predictions for Amphastar Pharmaceuticals Inc's Q1 2018 Earnings (AMPH)
www.americanbankingnews.com - March 15 at 7:37 AM |
| Amphastar Pharmaceuticals (AMPH) Q4 2017 Earnings Conference Call Transcript
finance.yahoo.com - March 14 at 5:25 PM |
| Amphastar Pharmaceuticals Inc (AMPH) Expected to Announce Quarterly Sales of $67.30 Million
www.americanbankingnews.com - March 14 at 12:12 PM |
| Amphastar Pharmaceuticals (AMPH) Lowered to "Hold" at Zacks Investment Research
www.americanbankingnews.com - March 13 at 4:35 PM |
| Amphastar Pharmaceuticals (AMPH) PT Raised to $19.00 at BMO Capital Markets
www.americanbankingnews.com - March 13 at 3:55 PM |
| Amphastar Pharmaceuticals (AMPH) Price Target Raised to $24.00
www.americanbankingnews.com - March 13 at 3:50 PM |
| Amphastar Pharmaceuticals' (AMPH) CEO Yongfeng Zhang on Q4 2017 Results - Earnings Call Transcript
seekingalpha.com - March 13 at 10:04 AM |
| Amphastar Pharmaceuticals (AMPH) Posts Quarterly Earnings Results, Beats Estimates By $0.03 EPS
www.americanbankingnews.com - March 12 at 9:10 PM |
| Amphastar Pharmaceutical Q4 Earnings Preview
finance.yahoo.com - March 12 at 5:18 PM |
| Amphastar beats Street 4Q forecasts
finance.yahoo.com - March 12 at 5:18 PM |
| Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Fiscal Year Ended December 31, 2017
finance.yahoo.com - March 12 at 5:18 PM |
| Amphastar Pharmaceuticals Inc (AMPH) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - March 10 at 6:12 PM |
| Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on March 12, 2018
finance.yahoo.com - March 5 at 4:48 PM |
| Amphastar Pharmaceuticals (AMPH) Cut to Sell at BidaskClub
www.americanbankingnews.com - March 3 at 6:10 PM |
| Should You Be Concerned About Amphastar Pharmaceuticals Inc’s (NASDAQ:AMPH) -98.57% Earnings Decline?
finance.yahoo.com - March 2 at 9:34 AM |
| Mallinckrodt PLC (MNK) Jumps: Stock Rises 15.3%
finance.yahoo.com - February 28 at 9:37 AM |
| How Did Amphastar Pharmaceuticals Inc’s (NASDAQ:AMPH) 0.09% ROE Fare Against The Industry?
finance.yahoo.com - February 22 at 9:29 AM |
| Key Factors to Influence Penumbra's (PEN) Earnings in Q4
finance.yahoo.com - February 21 at 9:53 AM |
| Amphastar Pharmaceuticals Inc (AMPH) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - February 13 at 5:36 PM |
| Amphastar Pharmaceuticals (AMPH) Rating Increased to Hold at BidaskClub
www.americanbankingnews.com - February 10 at 1:06 PM |
| $60.11 Million in Sales Expected for Amphastar Pharmaceuticals Inc (AMPH) This Quarter
www.americanbankingnews.com - February 8 at 6:02 AM |
| What's in Store for Cardinal Health (CAH) in Q2 Earnings?
finance.yahoo.com - January 30 at 9:21 AM |
| Insider Selling: Amphastar Pharmaceuticals Inc (AMPH) General Counsel Sells 8,661 Shares of Stock
www.americanbankingnews.com - January 27 at 12:12 AM |
Amphastar Pharmaceuticals (NASDAQ:AMPH) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Amphastar Pharmaceuticals (NASDAQ:AMPH) Income Statement, Balance Sheet and Cash Flow Statement
Amphastar Pharmaceuticals (NASDAQ AMPH) Stock Chart for Friday, April, 20, 2018
Loading chart…
